Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

not met at the highest dose evaluated as monotherapy (1000 mg). - No evidence of altered cardiac activity was observed. - Majority of adverse events were mild and mainly occurred during the loading doses. Adverse events consisted of chills, itching and fatigue in over a third of patients. - There was a trend for increasing incidence of some mild adverse events with escalating OGX-427 doses. For example, 33% of patients at the 200-mg dose compared to 67% of patients at the 1000-mg dose had mild adverse events during the loading doses. - The half-life of OGX-427 in the blood remained constant, although there appeared to be an increase in maximum blood levels and a corresponding decease in blood clearance of OGX-427 as doses were escalated.

The combination of 800 mg OGX-427 with docetaxel was also well tolerated and escalation to 1000 mg OGX-427 with docetaxel will be evaluated next.

Circulating Tumor Cell and Tumor Marker Results

Circulating tumor cells (CTCs), an emerging metric to assess treatment effect, was evaluated at baseline before treatment and during treatment. Both total and Hsp27-positive CTCs were evaluated. Declines of 50% or greater in both total and Hsp27-positive CTCs were observed in over half of the patients in each cohort and in each cancer category. Declines in Hsp27 CTCs to 5 or less cells occurred in 27% of patients who had greater than 5 CTCs at baseline.

Reduction in tumor markers defined as declines of PSA levels in prostate cancer or CA-125 levels in ovarian cancer were also observed. A reduction in PSA level was observed in 7 of 20 patients (35%) with prostate cancer and a reduction in CA-125 levels was observed in 3 of 5 patients (60%) with ovarian cancer.

"CTCs are emerging as an exciting surrogate of anti-cancer activity. The frequent decreases in total
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 Governor Andrew M. Cuomo today ... 43North - the world’s largest business idea competition with ... of $1 million, six $500,000 awards and four $250,000 ... to compete for prizes that will turn ideas with ... New York region. , "Last year's successful 43North ...
(Date:3/26/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... with certain matters, including the appointment of auditors, its ... 26, 2015 (the "Meeting") was adjourned, as previously disclosed ... 11:00 a.m. ( Toronto time). The ... that previous disclosed. The Meeting will reconvene at the ...
(Date:3/26/2015)... CINCINNATI , March 26, 2015 ... SHPG ) and Cincinnati Children,s Hospital Medical Center ... rare diseases. The goal of the collaboration is to ... diseases with high unmet medical need combining Shire,s ... expertise. As a nationally ranked hospital, Cincinnati Children,s ...
(Date:3/26/2015)... Texas (PRWEB) March 26, 2015 ReliantHeart, ... technologies, and Transonic, a supplier of precision transit-time flow ... that will greatly improve the efficiency of the ... enable LVAD patients to experience greater mobility and peace ... with the miniature flow board, will draw 1/6th of ...
Breaking Biology Technology:Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5SQI Diagnostics Inc. Announces Adjournment of Meeting 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... 2, 2011 This September, during Prostate Cancer Awareness ... cancer screening method that may change the face of ... Cleveland hospitals and one Boston hospital, analyzed by the National ... urine screening. Dr. David Samadi, Vice Chairman, Department of ...
...  Sept. 2, 2011  PTC Therapeutics, Inc. and ... of their collaboration. Under the original agreement, PTC ... and Genzyme held commercial rights in all other ... rights to ataluren and Genzyme retains an option ...
... This release is available in German . ... and MIT professor Ron Weiss have successfully incorporated a ... recognizes certain cancer cells using logic combinations of five ... (Kobi) Benenson, Professor of Synthetic Biology at ETH Zurich, ...
Cached Biology Technology:More Precise Prostate Cancer Screening on Horizon 2More Precise Prostate Cancer Screening on Horizon 3PTC Therapeutics and Genzyme Announce Restructuring of Collaboration 2PTC Therapeutics and Genzyme Announce Restructuring of Collaboration 3Profiler at the cellular level 2Profiler at the cellular level 3
(Date:3/12/2015)... 2015 The mascots of the Atlantic Coast ... of Wake Forest Baptist Medical Center. They stopped by ... ACC Men,s Basketball Tournament. Young patients enjoyed bonding with ... their autographs. Brenner Children,s Hospital is the ... only children,s hospital in northwest North Carolina ...
(Date:3/11/2015)... --  The Sync Project™ today announced the ... harness music to improve health. The platform maps ... of physiology, enabling the study of the therapeutic ... It is designed for medical and health research, ... and accelerate the discovery of the clinical applications ...
(Date:3/10/2015)... Conn. , March 10, 2015  NXT-ID, ... ("NXT-ID" or the "Company"), a biometric authentication company ... the company,s Wocket™ smart wallet has been named ... by Rethink Modern. Rethink Modern ( ... and innovative items for your home and lifestyle that have ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... Reston, Va.SNM is calling on Congress to support the ... Radiation Therapy Act (CARE bill), which would ensure that ... medicine technologists. The bill (H.R. 3652) was introduced Sept. ... John Barrow (D-Ga.). "The introduction of ...
... The American Society of Agronomy (ASA) strongly supports ... to improve water quality in the Mississippi River Basin. ... voluntary, incentive-based program. "Clean water and profitable crop ... that have been developed by ASA members. The initiative ...
... to develop as two of the most exciting areas ... public is almost completely unaware of the science and ... conducted by Peter D. Hart Research Associates and the ... of Americans think the public should be better informed ...
Cached Biology News:SNM urges Congress to support CARE bill 2Agronomy Society welcomes USDA Mississippi River Basin Initiative 2Nanotechnology and synthetic biology: What does the American public think? 2
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Raised to arginine vasopressin coupled to bovine thyroglobulin with carbodiimide ....
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Biology Products: